Champions Oncology Files 8-K with Exhibits

Ticker: CSBR · Form: 8-K · Filed: Jul 21, 2025 · CIK: 771856

Champions Oncology, INC. 8-K Filing Summary
FieldDetail
CompanyChampions Oncology, INC. (CSBR)
Form Type8-K
Filed DateJul 21, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: 8-K, financial-statements, exhibits

TL;DR

Champions Oncology filed an 8-K, mostly boilerplate but check exhibits for any surprises.

AI Summary

Champions Oncology, Inc. filed an 8-K on July 21, 2025, reporting financial statements and exhibits. The company, previously known as Champions Biotechnology, Inc., is incorporated in Delaware and has its principal executive offices in Hackensack, New Jersey.

Why It Matters

This filing indicates routine corporate activity and the submission of required financial documentation to the SEC.

Risk Assessment

Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, with no immediate indication of significant new risks.

Key Numbers

Key Players & Entities

FAQ

What specific financial statements or exhibits are being filed with this 8-K?

The filing indicates that financial statements and exhibits are being filed, but the specific details of these documents are not provided in the provided text.

When was the company's name last changed?

The company's name was last changed from Champions Biotechnology, Inc. on February 20, 2007.

What is the principal executive office address for Champions Oncology, Inc.?

The principal executive offices are located at 1 University Plaza, Suite 307, Hackensack, New Jersey 07601.

What is the Standard Industrial Classification (SIC) code for Champions Oncology, Inc.?

The SIC code is 2836, which corresponds to Biological Products (No Diagnostic Substances).

What is the fiscal year end for Champions Oncology, Inc.?

The fiscal year end for the company is April 30.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 21, 2025 regarding CHAMPIONS ONCOLOGY, INC. (CSBR).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing